Under the new system, Class 12 answer sheets will first be scanned after the examination. Examiners will then assess the digitised copies on a computer screen instead of marking physical ...

Under the new system, Class 12 answer books will be scanned and evaluated digitally by examiners. Teachers will mark scripts on a computer instead of handling physical copies.The Board stated that the ...

CBSE conducts Class 10 and Class 12 board examinations annually in India and across 26 countries. As part of its continued efforts to enhance efficiency, transparency, and speed in the evaluation ...

The Central Board of Secondary Education (CBSE) has announced the introduction of On-Screen Marking (OSM) system for the evaluation of Class 12 answer books from the upcoming 2026 board examinations, ...

ISC Class 12th Question Papers 2026: The ISC Class 12 examinations 2026 are conducting from 12th February to 6th April 2026 as per the schedule of the Council for the Indian School Certificate ...

CBSE Board Exam 2026: As the Central Board of Secondary Education (CBSE) Class 10 and 12 board exams are about to start on February 17, students need to learn about the changes that the board made in ...

RBSE Class 12 Topper Answer Sheet 2025: RBSE Class 12 board exams are a crucial milestone for students aiming to secure high marks and build a strong academic future. As the examinations are being ...

CBSE Class 12 Physics Paper 2026 Analysis: Teachers described it as easy to moderate, offering a balance between scoring opportunities and conceptual challenges.

Class 12 students say derivations and PYQs dominated Physics paper; Class 10 Marketing exam termed ‘very easy’ with many expecting 45+ marks.

When we hear about moving objects with electricity, most of us imagine a "pulling force." Positive and negative charges ...

World of Warcraft reveals the surprising backstory of Xal'atath, including the true, original form of Midnight's popular main antagonist. Every specialization except Demonology Warlock received at ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three months and full ...